EMA Authorised: Nexviadyme (avalglucosidase alfa) — Sanofi B.V.

View source ↗

Summary

EMA authorised Nexviadyme (avalglucosidase alfa) from Sanofi B.V. for Pompe disease (Glycogen Storage Disease Type II) with decision dated 06/08/2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• Nexviadyme (avalglucosidase alfa)

Snippet

Status: Authorised. Therapeutic area: Glycogen Storage Disease Type II. MAH: Sanofi B.V.. Decision date: 06/08/2024